Latest Articles about ARNA

ARNA Sheds Light on Belviq Launch - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 00:24:33 Z

Arena Pharmaceuticals Inc. ( ARNA ) recently announced that the US Drug Enforcement Administration (DEA) has assigned its obesity drug Belviq into Schedule IV of the Controlled Substances

Pre-Market Most Active for May 8, 2013 : BIP, BAC, CIE, BBRY, VCLK, VNTV, TLK, CFX, SODA, ARNA, SIRI, FB

NASDAQ.com News — Wed, 08 May 2013 16:39:39 Z

The NASDAQ 100 Pre-Market Indicator is up .89 to 2,953.77. The total Pre-Market volume is currently 2,501,382 shares traded. The following are the most active stocks for the pre-market

Arena Pharma Narrows Loss - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 19:21:53 Z

Arena Pharmaceuticals Inc. 's ( ARNA ) loss (excluding special items) of 10 cents per share in the first quarter of 2013 was narrower than the year-ago loss of 15 cents per share. The Zacks

Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data

Scott Rubin — Sat, 04 May 2013 00:28:54 Z

The U.S. stock market jumped on Friday to end the trading week. The catalyst for the move higher was a strong jobs report, which briefly sent the Dow Jones Industrial Average over 15,000 for

Mid-Morning Market Update: Markets Surge On Jobs Data, Dow Breaks 15,000 for the First Time in History

Jake L'Ecuyer — Fri, 03 May 2013 18:32:52 Z

Following the market opening Friday, the Dow traded up 1.01 percent to 14,981.68 while the NASDAQ surged 1.26 percent to 3,382.65. The S&P also rose, gaining 1.08 percent to 1,614.82.

Pre-Market Most Active for May 3, 2013 : CETV, BAC, ARNA, SPIL, FB, QQQ, AIG, NVS, DB, SIRI, NOK, ABX

NASDAQ.com News — Fri, 03 May 2013 16:40:00 Z

The NASDAQ 100 Pre-Market Indicator is up 10.37 to 2,921.51. The total Pre-Market volume is currently 7,627,528 shares traded. The following are the most active stocks for the pre-market

After Hours Most Active for May 2, 2013 : QQQ, AIG, LNKD, AMX, ARNA, FB, NCT$, NCT, NRZ$, NWSA, MSFT, DTV

NASDAQ.com News — Fri, 03 May 2013 00:45:02 Z

The NASDAQ 100 After Hours Indicator is down -1.46 to 2,909.68. The total After hours volume is currently 25,803,799 shares traded. The following are the most active stocks for the after

Weekly Preview: Focus Shifts from Earnings to Economy

Matthew Kanterman — Sat, 27 Apr 2013 00:35:00 Z

In the upcoming week, the focus of markets will gradually shift from earnings to the economy, especially later in the week, as key reports including the ECB rate decision and the U.S. Non-Farm

Best Stocks: Biotech Still Holding Top Spots

StateOfTheMarkets.com — Mon, 22 Apr 2013 18:00:00 Z

At StateoftheMarkets.com, we focus our attention on the top-rated stocks of the market for a few simple reasons. The top stocks have the best earnings strength. The top stocks have strong

Expanded Access for VIVUS' Qsymia - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:10:09 Z

VIVUS, Inc. ( VVUS ) recently announced that the amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) of its obesity drug, Qsymia (phentermine and topiramate

Patients Dosed in Arena Study - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 02:09:14 Z

Arena Pharmaceuticals, Inc. ( ARNA ) recently announced that patient dosing in a randomized, double-blind and placebo-controlled phase I study being conducted on APD334 has commenced. The

WEEKLY CFO SELLS HIGHLIGHT: ZNGA, ARNA, JACK, TUMI, PANW

gurujx — Mon, 08 Apr 2013 02:06:03 Z

According to GuruFocus Insider Data , the largest CFO sells during the past week were: Zynga Inc., Arena Pharmaceuticals Inc., Jack In The Box Inc., Tumi Holdings Inc. and Palo Alto Networks

ARNA/Eisai's Belviq Filed in Mexico - Analyst Blog

Zacks Equity Research — Thu, 04 Apr 2013 00:19:58 Z

Arena Pharmaceuticals, Inc. ( ARNA ) recently announced that Eisai Laboratories S. de R.L. de C.V, a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for

Vivus Opts for Royalty Financing - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 03:21:59 Z

Vivus, Inc. ( VVUS ) recently announced that it has entered into an agreement with a Pharmakon Advisors managed investment fund for a $110 million non-equity financing. Vivus will initially

Loss at OREX Narrower than Expected - Analyst Blog

Mark Vickery — Fri, 15 Mar 2013 01:45:16 Z

Orexigen Therapeutics, Inc. ( OREX ) reported a net loss of 41 cents per share in the fourth quarter of 2012, much wider than the year-ago loss of 9 cents but 4 cents narrower than the